Literature DB >> 25838374

Adoptive cell transfer as personalized immunotherapy for human cancer.

Steven A Rosenberg1, Nicholas P Restifo1.   

Abstract

Adoptive cell therapy (ACT) is a highly personalized cancer therapy that involves administration to the cancer-bearing host of immune cells with direct anticancer activity. ACT using naturally occurring tumor-reactive lymphocytes has mediated durable, complete regressions in patients with melanoma, probably by targeting somatic mutations exclusive to each cancer. These results have expanded the reach of ACT to the treatment of common epithelial cancers. In addition, the ability to genetically engineer lymphocytes to express conventional T cell receptors or chimeric antigen receptors has further extended the successful application of ACT for cancer treatment.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25838374      PMCID： PMC6295668          DOI： 10.1126/science.aaa4967

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  751 in total

1.  Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.

Authors:  Pritha Agarwalla; Edikan A Ogunnaike; Sarah Ahn; Frances S Ligler; Gianpietro Dotti; Yevgeny Brudno
Journal:  Adv Healthc Mater       Date:  2020-06-11       Impact factor: 9.933

2.  Raising the bar: optimizing combinations of targeted therapy and immunotherapy.

Authors:  Alexandre Reuben; Jacob Austin-Breneman; Jennifer A Wargo; Zachary A Cooper
Journal:  Ann Transl Med       Date:  2015-10

Review 3.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

Review 4.  Cellular immunotherapy for malignant gliomas.

Authors:  Yi Lin; Hideho Okada
Journal:  Expert Opin Biol Ther       Date:  2016-07-29       Impact factor: 4.388

5.  PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.

Authors:  Jan Budczies; Gunhild Mechtersheimer; Carsten Denkert; Frederick Klauschen; Sadaf S Mughal; Priya Chudasama; Michael Bockmayr; Korinna Jöhrens; Volker Endris; Amelie Lier; Felix Lasitschka; Roland Penzel; Manfred Dietel; Benedikt Brors; Stefan Gröschel; Hanno Glimm; Peter Schirmacher; Marcus Renner; Stefan Fröhling; Albrecht Stenzinger
Journal:  Oncoimmunology       Date:  2017-01-27       Impact factor: 8.110

6.  Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients.

Authors:  Pavla Taborska; Dmitry Stakheev; Zuzana Strizova; Katerina Vavrova; Michal Podrazil; Jirina Bartunkova; Daniel Smrz
Journal:  Med Oncol       Date:  2017-09-02       Impact factor: 3.064

Review 7.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

8.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.

Authors:  Dyantha I van der Lee; Rogier M Reijmers; Maria W Honders; Renate S Hagedoorn; Rob Cm de Jong; Michel Gd Kester; Dirk M van der Steen; Arnoud H de Ru; Christiaan Kweekel; Helena M Bijen; Inge Jedema; Hendrik Veelken; Peter A van Veelen; Mirjam Hm Heemskerk; J H Frederik Falkenburg; Marieke Griffioen
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

Review 9.  Cancer vaccines: translation from mice to human clinical trials.

Authors:  Hoyoung Maeng; Masaki Terabe; Jay A Berzofsky
Journal:  Curr Opin Immunol       Date:  2018-03-16       Impact factor: 7.486

10.  Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.

Authors:  Yi Zheng; Yicheng Yang; Shu Wu; Yongqiang Zhu; Xiaolong Tang; Xiaopeng Liu
Journal:  Bioengineered       Date:  2016-10-18       Impact factor: 3.269
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.